SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models

[1]  J. Williams,et al.  Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field , 2018, Journal of clinical medicine.

[2]  Z. Zeng,et al.  Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities , 2018, Molecular Cancer.

[3]  Cécile Chalouni,et al.  Fate of Antibody-Drug Conjugates in Cancer Cells , 2018, Journal of Experimental & Clinical Cancer Research.

[4]  A. Avan,et al.  C‐Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives , 2017, Journal of cellular physiology.

[5]  Jinbiao Zhan,et al.  Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates , 2017, Drug design, development and therapy.

[6]  P. Liu,et al.  Targeting MET in cancer therapy , 2017, Chronic diseases and translational medicine.

[7]  Huyuan Yang,et al.  A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C , 2017, Investigational New Drugs.

[8]  Peng Li,et al.  Current status and perspectives of patient-derived xenograft models in cancer research , 2017, Journal of Hematology & Oncology.

[9]  G. Gerken,et al.  Tivantinib for the treatment of hepatocellular carcinoma , 2017, Expert opinion on pharmacotherapy.

[10]  J. Bendell,et al.  Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C , 2017, Investigational New Drugs.

[11]  M. Birrer,et al.  Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Dong-Wan Kim,et al.  MINI01.03: Phase (Ph) I Study of the Safety and Efficacy of the cMET Inhibitor Capmatinib (INC280) in Patients with Advanced cMET+ NSCLC: Topic: Medical Oncology , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  Kedar S Vaidya,et al.  ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both MET–Amplified and c-Met–Overexpressing Tumors, Irrespective of MET Pathway Dependence , 2016, Clinical Cancer Research.

[14]  J. Nemunaitis,et al.  Phase 1, open-label, dose-escalation and expansion study of ABBV-399, an antibody drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors. , 2016 .

[15]  Kedar S Vaidya,et al.  Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification , 2016, BMC Cancer.

[16]  Yulei N. Wang,et al.  Phase I Study of DMOT4039A, an Antibody–Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer , 2016, Molecular Cancer Therapeutics.

[17]  Shi Xu.  Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates , 2015, Pharmaceutical Research.

[18]  A. Granito,et al.  c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma , 2015, Journal of hepatocellular carcinoma.

[19]  W. You,et al.  Development of antibody-based c-Met inhibitors for targeted cancer therapy , 2015, ImmunoTargets and therapy.

[20]  Weiguo Qing,et al.  Volitinib, a potent and highly selective c‐Met inhibitor, effectively blocks c‐Met signaling and growth in c‐MET amplified gastric cancer patient‐derived tumor xenograft models , 2015, Molecular oncology.

[21]  K. Garber.  MET inhibitors start on road to recovery , 2014, Nature Reviews Drug Discovery.

[22]  C. Sheridan.  Genentech to salvage anti-MET antibody with subgroup analysis , 2014, Nature Biotechnology.

[23]  G. Forte,et al.  Agonist monoclonal antibodies against HGF receptor protect cardiac muscle cells from apoptosis. , 2010, American journal of physiology. Heart and circulatory physiology.

[24]  I. Kasman,et al.  MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. , 2007, Cancer research.

[25]  K. Rex,et al.  AMG 102, A Fully Human Anti-Hepatocyte Growth Factor/Scatter Factor Neutralizing Antibody, Enhances the Efficacy of Temozolomide or Docetaxel in U-87 MG Cells and Xenografts , 2007, Clinical Cancer Research.

[26]  E Medico,et al.  Expression of the Met/HGF receptor in normal and neoplastic human tissues. , 1991, Oncogene.

[27]  M. Ghate,et al.  Recent advances in the discovery of small molecule c-Met Kinase inhibitors. , 2018, European journal of medicinal chemistry.

[28]  S. Khan,et al.  Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. , 2018, Pharmaceuticals.

[29]  J. Shih,et al.  A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population. , 2017, Lung cancer.

[30]  C. Grüllich.  Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. , 2014, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[31]  Corey D. Fogleman.  in cAncer tHerAPy , 2012 .

[32]  J. Obrecht.  [Cancer therapy]. , 1977, Deutsche medizinische Wochenschrift.